Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 24, 2006

EvoGenix Finetunes a GSK Therapeutic

  • EvoGenix has developed improved versions of a protein from GlaxoSmithKline’s (GSK) pipeline using its protein optimization technology, EvoGene™.

    "Our technology has been used to finetune the properties of potentially valuable therapeutics," informs EvoGenix CEO, Merilyn Sleigh, “to give them the best chance of success in treating patients safely and effectively, and of going on to become valuable products in the market place."

    GSK will be responsible for all subsequent development of the product, with EvoGenix eligible to earn a number of milestone payments as each product progresses through clinical testing toward the market. EvoGenix will also earn royalty payments on sales of products marketed successfully.



Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »